Ocular Therapeutix Inc. (NASDAQ:OCUL)’s share price fell 1.5% on Monday . The stock traded as low as $6.50 and last traded at $6.65, with a volume of 276,845 shares changing hands. The stock had previously closed at $6.75.

Several research firms have weighed in on OCUL. JMP Securities began coverage on Ocular Therapeutix in a research note on Thursday, August 11th. They issued an “outperform” rating and a $5.84 target price on the stock. BTIG Research reaffirmed a “buy” rating and set a $18.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, July 26th. Morgan Stanley reaffirmed an “overweight” rating and set a $16.00 price target (down previously from $17.00) on shares of Ocular Therapeutix in a research report on Tuesday, June 7th. Cowen and Company reaffirmed a “buy” rating on shares of Ocular Therapeutix in a research report on Monday, June 6th. Finally, Zacks Investment Research raised Ocular Therapeutix from a “hold” rating to a “buy” rating and set a $7.50 price target on the stock in a research report on Friday, August 12th. Six equities research analysts have rated the stock with a buy rating, Ocular Therapeutix presently has a consensus rating of “Buy” and an average target price of $19.07.

The stock’s 50 day moving average price is $6.56 and its 200 day moving average price is $8.18. The stock’s market cap is $170.77 million.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.03. Ocular Therapeutix had a negative return on equity of 52.44% and a negative net margin of 2,519.61%. The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $0.55 million. During the same quarter in the prior year, the company earned ($0.45) EPS. The firm’s revenue for the quarter was down 3.9% compared to the same quarter last year. On average, equities research analysts expect that Ocular Therapeutix Inc. will post ($1.87) earnings per share for the current year.

Large investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in Ocular Therapeutix by 1.5% in the first quarter. Geode Capital Management LLC now owns 70,396 shares of the biopharmaceutical company’s stock worth $680,000 after buying an additional 1,042 shares during the period. State Street Corp increased its position in Ocular Therapeutix by 13.8% in the first quarter. State Street Corp now owns 205,586 shares of the biopharmaceutical company’s stock worth $1,989,000 after buying an additional 24,939 shares during the period. Columbus Circle Investors increased its position in Ocular Therapeutix by 47.9% in the second quarter. Columbus Circle Investors now owns 278,785 shares of the biopharmaceutical company’s stock worth $1,380,000 after buying an additional 90,283 shares during the period. BlackRock Group LTD increased its position in Ocular Therapeutix by 980.8% in the first quarter. BlackRock Group LTD now owns 13,142 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 11,926 shares during the period. Finally, BlackRock Fund Advisors increased its position in Ocular Therapeutix by 1.5% in the first quarter. BlackRock Fund Advisors now owns 703,729 shares of the biopharmaceutical company’s stock worth $6,798,000 after buying an additional 10,320 shares during the period. Institutional investors own 78.45% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

5 Day Chart for NASDAQ:OCUL

Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.